Eli Lilly & Co. (LLY)
Last updated: 2026-11-17 02:00:01. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Eli Lilly & Co. (LLY) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $1,432.96, with a market capitalization of $1.29T and a P/E ratio of 46.62. Over the past 52 weeks, its price has ranged from $850.51 to $1,474.42. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.29T | |
$1,453.75 | |
$1,474.42 | |
$1,428.12 | |
$1,443.50 | |
2.19M | |
2.59M | |
46.62 | |
$1,474.42 | |
$850.51 | |
0.47% | |
12-31 |
Eli Lilly & Co. (LLY) Latest Closing Stock Price
Eli Lilly & Co. (LLY) last closed at $1,432.96 as of 2026-11-17 00:59:10, down 0.52% ($7.50) from the previous close of $1,443.50.
During the latest regular trading session, LLY traded between $1,428.12 and $1,474.42, with a volume of 2.19M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Eli Lilly & Co. (LLY) 7-Day Stock Price Change
Over the past seven days, Eli Lilly & Co. (LLY) moved from $1,364.73 to $1,432.96, representing a gain of 5.00% ($68.23).
The stock traded between $1,333.22 and $1,474.42 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 3.16 million shares, down versus the previous seven-day period, indicating lower trading activity.
LLY 52-Week Price Position
Position in Range: 93.4%
LLY is currently trading at $1,432.96, placing it 93.4% of the way from its 52-week low of $850.51 to its 52-week high of $1,474.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Eli Lilly & Co. (LLY)?
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly & Co. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 50,000 |
| CEO | David A. Ricks |
| Founded | 1876 |
| Exchange | NYSE |
| Company Website |
LLY Stock Events
View the latest dividend and stock split events for Eli Lilly & Co.
Dividend | |
|---|---|
| Ex-Dividend Date | Nov 13, 2026 |
| Payment Date | Dec 10, 2026 |
| Dividend Per Share | $1.73 |
LLY News
Latest news related to Eli Lilly & Co. and LLY stock.
- Read Full Article
- Read Full Article
Defensives Lead Sectors Monday As Growth Trails
Four sectors are higher and seven are lower in Monday’s regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than widely separated, with the top three staying within a narrow range of one another.
- Read Full Article
Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion As ObesityWeek Data Roll In
Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion and presents new Phase 2 and Phase 3 cardiometabolic data at ObesityWeek 2026.
- Read Full Article
Barclays Maintains Overweight on Eli Lilly, Raises Price Target to $1550
Barclays analyst Emily Field maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1400 to $1550.
- Read Full Article
Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and projected to reach USD 64.96 billion by 2035 at a 24.71% CAGR. Eli Lilly and Novo Nordisk dominate with strong Q3 2026 results, while Pfizer, Roche, and Amgen are investing billions to compete. Key trends include oral GLP-1 formulations, higher efficacy rates (>20% weight loss), and significant manufacturing capacity investments.
Ways to Trade LLY at MEXC
How to Buy Eli Lilly & Co. (LLY) Stock on MEXC
Eligible investors can buy real shares of Eli Lilly & Co. (LLY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Eli Lilly & Co. (LLY) stock price today?
2.Is LLY stock going up or down today?
3.What is LLY pre-market price?
4.What is LLY after-hours price?
5.Is LLY stock trading now?
6.Where does LLY sit relative to its 52-week high and low?
7.What sector is Eli Lilly & Co. in?
8.What is Eli Lilly & Co.'s market capitalization and where is it listed?
9.How is LLY valued in terms of P/E ratio and EPS?
10.Does Eli Lilly & Co. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LLY, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
LLY Stock Calculator
Estimate the value between LLY shares and USD.
LLY Shares to USD
1.00 LLY shares = 1,432.963 USD
Calculations are estimates based on the latest available price and are for reference only.


